Custom Search

News

Friday 01 November 2002

Effects of rituximab on a patient with Waldenstrom's macroglobulinaemia with deletion 13q14.

By: Mori A, Tamaru J, Kondo H.

Eur J Haematol 2002 Nov-Dec;69(5-6):321-3

The haematological and serological responses of Waldenstrom's macroglobulinaemia (WM) to rituximab have been recently reported, but there have been few reports examining the genetic responses of the drug in the treatment of WM. We report here a case of WM associated with deletion 13q14 and JH gene rearrangement that was successfully treated with rituximab alone. Three months after the therapy, the patient achieved haematological remission with the disappearance of constitutional symptoms and chromosomal abnormalities; however, the remission was partial, because the serum monoclonal immunoglobulin M and JH gene rearrangement persisted. Our case demonstrates that first-line therapy with rituximab is clinically and cytogenetically beneficial for WM.

Use of this site is subject to the following terms of use